Literature DB >> 1600049

Does a previous course of tripotassium dicitrato bismuthate affect the subsequent chances of successful Helicobacter pylori eradication?

G D Bell1, K Powell, S M Burridge, G Harrison, J Weil, P W Gant, P H Jones, J E Trowell.   

Abstract

We have performed a retrospective study of 103 patients with either peptic ulcer or non-ulcer dyspepsia, infected with metronidazole-sensitive strains of Helicobacter pylori (H. pylori), who were treated with a combination of tripotassium dicitrato bismuthate and metronidazole for a period of at least two weeks. Dual therapy with tripotassium dicitrato bismuthate plus metronidazole showed similarly high eradication rates (greater than or equal to 80%) of H. pylori from patients irrespective of age, gender or clinical diagnosis. Most importantly, dual therapy achieved a similar eradication rate of H. pylori infection in 41 patients who had previously been treated with tripotassium dicitrato bismuthate alone or in combination with an antibiotic other than metronidazole. It therefore appears that H. pylori does not become resistant to treatment with tripotassium dicitrato bismuthate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600049     DOI: 10.1111/j.1365-2036.1992.tb00054.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  2 in total

Review 1.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

2.  Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.

Authors:  T J Borody; P Andrews; G Fracchia; S Brandl; N P Shortis; H Bae
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.